Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cannabinoids Trigger Cellular Removal Of Alzheimer’s Disease-Associated Protein Plaques

XTALKS VITALS NEWS

 photo Neurons600_zpscmaoa1oz.jpg

The experiments conducted on neurons in cell culture highlight the role of inflammation in the neurodegenerative disease, and could help drugmakers develop novel treatments.

Share this!

Tweet: THC helps neurons remove amyloid beta associated with #Alzheimers disease http://ctt.ec/8IA6p+THC helps neurons remove amyloid beta associated with Alzheimer's disease.

Tweet: NIH: over five million Americans are affected by #Alzheimers disease http://ctt.ec/1_Wp7+NIH: over five million Americans are affected by Alzheimer’s disease.

June 30, 2016 | by Sarah Massey, M.Sc.

Researchers at the Salk Institute in California have discovered that compounds found in cannabis – including tetrahydrocannabinol (THC) – may help neurons remove protein clumps of amyloid beta, which have been associated with Alzheimer’s disease. The experiments conducted on neurons in cell culture highlight the role of inflammation in the neurodegenerative disease, and could help drugmakers develop novel treatments.

“Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer's, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells,” said Dr. David Schubert, a professor at the Salk Institute and an author on the paper. The research was published in the journal, Aging and Mechanisms of Disease.

According to the National Institutes of Health (NIH), over five million Americans are affected by Alzheimer’s disease. The degenerative disease is the most common cause of dementia and is a leading cause of death in the US.

Amyloid beta protein begins to accumulate within the neurons of the brain even before any Alzheimer’s disease-associated symptoms begin to manifest. While amyloid beta plaques are associated with the disease, it’s unclear whether their formation is causative of Alzheimer’s.

In studying human nerve cells designed to overexpress amyloid beta protein, Schubert and his colleagues found that the high protein levels were associated with cellular inflammation and increased incidence of cell death. After exposing the cells to THC, the researchers found that the levels of amyloid beta protein were lowered, and the inflammatory response elicited by the protein plaques was eliminated.



“Inflammation within the brain is a major component of the damage associated with Alzheimer's disease, but it has always been assumed that this response was coming from immune-like cells in the brain, not the nerve cells themselves,” said Antonio Currais, a postdoctoral researcher in Schubert's laboratory and primary author on the paper. “When we were able to identify the molecular basis of the inflammatory response to amyloid beta, it became clear that THC-like compounds that the nerve cells make themselves, may be involved in protecting the cells from dying.”

Endocannabinoids – lipid molecules that are endogenously present in the brain – act as intercellular signals that bind to their receptors on adjacent neurons. As THC derived from cannabis is similar to the endocannabinoids found in the brain, it is also able to bind to those same receptors.

While the results point to THC and the endocannabinoid receptor as a potential target for future Alzheimer’s therapies, the researchers caution the studies so far have only been conducted in cell culture. In order to test the safety and efficacy of THC-like compounds on humans, the drug would need to be studied further in clinical trials.


Keywords: Alzheimer's Disease, Amyloid Beta, Neuron


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.